What is Invokana?
Invokana, also known by its generic name of canagliflozin, is a relatively new drug, manufactured by Johnson & Johnson, that has only gained popularity in the last two years or so. Approved by the Food and Drug Administration (FDA) in 2013, Invokana is the first drug of its kind used to treat Type II diabetes. People with Type II diabetes are unable to process sugar normally and become resistant to insulin, leading to a dangerous buildup of excess sugar in the body. Invokana is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that simply works to stop sugar from being reabsorbed into the patient’s blood.
Understanding the dangers and risks associated with the use of Invokana
Shortly after its introduction into the market in 2013, many patients began experiencing significant side effects and complications after starting an Invokana regimen. In May 2015, the FDA issued a safety warning to patients and doctors advising that SGLT2 inhibitors, such as Invokana, are now known to lead to diabetic ketoacidosis (DKA). DKA occurs when the body begins breaking down fat for energy leading to the production of toxic ketones. DKA is a serious medical condition that requires emergency treatment. The most common symptoms of DKA include:
Shortness of breath
Muscle aches and stiffness
Nausea, vomiting and stomach pain
Patients suspected of having DKA are forced to undergo numerous blood tests for diagnosis. Treatment of DKA often includes rigorous intravenous fluid, electrolyte and insulin therapy.
FDA Warning Over SGLT2 inhibitors for diabetes
Last year, the U.S. Food and Drug Administration (FDA) issued a warning over type 2 diabetes medicines, including canagliflozin (a k a Invokana), dapagliflozin, and empagliflozin. The warning advised patients that taking these drugs may lead to ketoacidosis, a serious condition that causes high levels of blood acids called ketones.
Subsequently, in December 2015, the FDA revised labels of SGLT2 inhibitors to include explicit warnings over too high blood acid levels and serious urinary tract infections.
Unsafe Drug Attorneys - Pennsylvania & New Jersey
If you or someone you know has suffered as a result of the drug Invokana or its generic equivalent canagliflozin, please contact our attorneys immediately for a free consultation toll-free at 215-462-3330 or by using our online contact form.